Arcutis Reports the US Launch of Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis
Shots:
- Arcutis has introduced Zoryve topical foam, 0.3%, across the US to treat patients (9yrs. and older) with seborrheic dermatitis. It was approved by the US FDA in Dec 2023
- The patient support program, Zoryve Direct Program, will help patients find the payer process, supports adherence and includes the Zoryve Direct Savings Card Program to lower out-of-pocket for commercially insured patients. Arcutis Cares PAP will provide the drug at no cost to the financially eligible uninsured/underinsured patients
- Zoryve (QD), steroid-free foam, reduces inflammation and symptoms in patients with plaque psoriasis and seborrheic dermatitis
Ref: Arcutis | Image: Arcutis
Related News:- Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
